¹Paediatric Onco-Haematology and Stem Cell Transplantation and Cellular Therapy Unit, Regina Margherita Children's Hospital, Turin, Italy

Correspondence: Professor F Fagioli, Paediatric Onco-Haematology and Stem Cell Transplantation and Cellular Therapy Unit, Regina Margherita Children's Hospital, Turin, Italy. E-mail: franca.fagioli@unito.it

Abstract

First-line treatment of GVHD is based on steroids and produces sustained responses in 50–80% of patients with acute GVHD (aGVHD) and 40–50% of patients with chronic GVHD (cGVHD) depending on the initial disease severity. Non-responding children are offered second-line therapy with combinations of various agents, but currently available agents have not improved survival in these high-risk populations. In this minireview, we will focus on new agents to treat GVHD in paediatric patients.